Does Arterial Hypertension Affect Plasma Levels of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Stable Coronary Artery Disease? A Preliminary Study
Table 1
Characteristics of the study population.
Clinical parameter
CAD group
Statistical significance: arterial hypertension vs no arterial hypertension group
Arterial hypertension
No arterial hypertension
Total number of patients (%)
57
13
Age (years), mean ± S.E.M.
62.4 ± 8.3
57.3 ± 8.9
ns
Sex
ns
Men
44
11
Women
13
2
Clinical characteristics
Coronary artery disease
ns
CCS II
50
12
CCS III
7
1
Diabetes mellitus
32
2
Current tobacco use
19
6
ns
History of myocardial infarction
29
5
ns
History of PCI/CABG >3 months before study
PCI 22 CABG 8
PCI 6 CABG 2
ns
History of stroke or TIA >3 months before study
4
1
ns
Kidney insufficiency (GFR <60 ml/min/m2)
11
4
ns
Hypercholesterolemia
55
10
ns
HbA1C, mean ± SD
6.5 ± 3.4
5.9 ± 2.8
ns
Drug administration
Beta-blocker
57
10
ns
Calcium channel blockers
42
2
ns
ACE-I
55
6
ns
ARB
13
2
ns
Statins
57
13
ns
Oral antidiabetic drugs
28
2
ns
Insulin
20
1
ns
ACE-I: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CABG: coronary artery by-pass grafting; CAD: coronary artery disease; GFR: glomerular filtration rate; HbA1C: glycated hemoglobin A1C; NA: not analysed; NS: statistically not significant; PCI: percutaneous coronary intervention; SD: standard deviation; TIA: transient ischemic attack. CCS: Canadian Cardiovascular Society classification of coronary artery disease clinical status. χ2 Yates.
